SDS-Page
(The purity of T8250-13B was determined by SDS-PAGE of 6ug reduced (+) and non-reduced (-) recombinant hTGF-β1 and staining overnight with Coomassie Blue.)
Transforming Growth Factor beta1, Ala279-Ser390 Recombinant Protein | TGFB1 recombinant protein
Transforming Growth Factor beta1, Recombinant, Human, Ala279-Ser390 (TGF beta 1, TGFb1, Camurati Engelmann Disease, CED, Diaphyseal Dysplasia 1 Progressive, DPD1, TGFb1, Differentiation Inhibiting Factor, Cartilage-inducing Factor)
98% by SDS-PAGE of 6ug reduced (+) and non-reduced (-) recombinant human TGFb1. <1% migrates as monomer human TGFb1 under non-reduced (-) conditions. Endotoxin: 0.01ng/ug
98% by SDS-PAGE of 6ug reduced (+) and non-reduced (-) recombinant human TGFb1. <1% migrates as monomer human TGFb1 under non-reduced (-) conditions. Endotoxin: 0.01ng/ug
SDS-Page
(The purity of T8250-13B was determined by SDS-PAGE of 6ug reduced (+) and non-reduced (-) recombinant hTGF-β1 and staining overnight with Coomassie Blue.)
SDS-Page
(The purity of T8250-13B was determined by SDS-PAGE of 6ug reduced (+) and non-reduced (-) recombinant hTGF-β1 and staining overnight with Coomassie Blue.)
Testing Data
(The inhibition of IL-4 induced proliferation in HT-2 cells treated with increasing concentrations of T8250-13B was assessed. After 48 hour treatment with T8250-13B, cells were incubated with a tetrazolium salt and the OD450 - OD650 was determined.)
Testing Data
(The inhibition of IL-4 induced proliferation in HT-2 cells treated with increasing concentrations of T8250-13B was assessed. After 48 hour treatment with T8250-13B, cells were incubated with a tetrazolium salt and the OD450 - OD650 was determined.)
Western Blot (WB)
(Western Blot analysis of extracts from HeLa cells, untreated or treated with T8250-13B for 25 minutes, using Phospho-Smad2 (Ser465/467) mAb and Smad2 Rabbit mAb (lower).)
Western Blot (WB)
(Western Blot analysis of extracts from HeLa cells, untreated or treated with T8250-13B for 25 minutes, using Phospho-Smad2 (Ser465/467) mAb and Smad2 Rabbit mAb (lower).)
Recombinant human TGFb1 contains no "tags" and the nonglycosylated protein has a calculated MW of 12,794. DTT-reduced protein migrates as a 13kD polypeptide and the non-reduced cystine-linked homodimer migrates as a 25kD protein. The expected amino-terminal ALDTN of recombinant human TGFb1 was verified by amino acid sequencing.
NCBI and Uniprot Product Information
NCBI Description
This gene encodes a member of the transforming growth factor beta (TGFB) family of cytokines, which are multifunctional peptides that regulate proliferation, differentiation, adhesion, migration, and other functions in many cell types. Many cells have TGFB receptors, and the protein positively and negatively regulates many other growth factors. The secreted protein is cleaved into a latency-associated peptide (LAP) and a mature TGFB1 peptide, and is found in either a latent form composed of a TGFB1 homodimer, a LAP homodimer, and a latent TGFB1-binding protein, or in an active form composed of a TGFB1 homodimer. The mature peptide may also form heterodimers with other TGFB family members. This gene is frequently upregulated in tumor cells, and mutations in this gene result in Camurati-Engelmann disease.
Uniprot Description
Function: Multifunctional protein that controls proliferation, differentiation and other functions in many cell types. Many cells synthesize TGFB1 and have specific receptors for it. It positively and negatively regulates many other growth factors. It plays an important role in bone remodeling as it is a potent stimulator of osteoblastic bone formation, causing chemotaxis, proliferation and differentiation in committed osteoblasts.
Subunit structure: The inactive form consists of a TGFB1 homodimer non-covalently linked to a latency-associated peptide (LAP) homodimer. The inactive complex can contain a latent TGFB1-binding protein. The active form is a homodimer of mature TGFB1; disulfide-linked. Heterodimers of TGFB1/TGFB2 have been found in bone. Interacts with CD109 and DPT. Interacts with ASPN. Ref.12 Ref.15 Ref.17
Subcellular location: Secreted › extracellular space › extracellular matrix Ref.17.
Tissue specificity: Highly expressed in bone. Abundantly expressed in articular cartilage and chondrocytes and is increased in osteoarthritis (OA). Co-localizes with ASPN in chondrocytes within OA lesions of articular cartilage. Ref.13 Ref.17
Induction: Activated in vitro at pH below 3.5 and over 12.5.
Post-translational modification: Glycosylated. Ref.14 Ref.16The precursor is cleaved into mature TGF-beta-1 and LAP, which remains non-covalently linked to mature TGF-beta-1 rendering it inactive.
Polymorphism: In post-menopausal Japanese women, the frequency of Leu-10 is higher in subjects with osteoporosis than in controls.
Involvement in disease: Defects in TGFB1 are the cause of Camurati-Engelmann disease (CE) [
MIM:131300]; also known as progressive diaphyseal dysplasia 1 (DPD1). CE is an autosomal dominant disorder characterized by hyperostosis and sclerosis of the diaphyses of long bones. The disease typically presents in early childhood with pain, muscular weakness and waddling gait, and in some cases other features such as exophthalmos, facial paralysis, hearing difficulties and loss of vision. Ref.22 Ref.23 Ref.25 Ref.26
Sequence similarities: Belongs to the TGF-beta family.
Research Articles on TGFB1
Similar Products
Product Notes
The TGFB1 tgfb1 (Catalog #AAA650868) is a Recombinant Protein and is intended for research purposes only. The product is available for immediate purchase. The Transforming Growth Factor beta1, Recombinant, Human, Ala279-Ser390 (TGF beta 1, TGFb1, Camurati Engelmann Disease, CED, Diaphyseal Dysplasia 1 Progressive, DPD1, TGFb1, Differentiation Inhibiting Factor, Cartilage-inducing Factor) reacts with Human and may cross-react with other species as described in the data sheet. AAA Biotech's Transforming Growth Factor beta1, Ala279-Ser390 can be used in a range of immunoassay formats including, but not limited to, Western Blot (WB). Researchers should empirically determine the suitability of the TGFB1 tgfb1 for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process. It is sometimes possible for the material contained within the vial of "Transforming Growth Factor beta1, Ala279-Ser390, Recombinant Protein" to become dispersed throughout the inside of the vial, particularly around the seal of said vial, during shipment and storage. We always suggest centrifuging these vials to consolidate all of the liquid away from the lid and to the bottom of the vial prior to opening. Please be advised that certain products may require dry ice for shipping and that, if this is the case, an additional dry ice fee may also be required.Precautions
All products in the AAA Biotech catalog are strictly for research-use only, and are absolutely not suitable for use in any sort of medical, therapeutic, prophylactic, in-vivo, or diagnostic capacity. By purchasing a product from AAA Biotech, you are explicitly certifying that said products will be properly tested and used in line with industry standard. AAA Biotech and its authorized distribution partners reserve the right to refuse to fulfill any order if we have any indication that a purchaser may be intending to use a product outside of our accepted criteria.Disclaimer
Though we do strive to guarantee the information represented in this datasheet, AAA Biotech cannot be held responsible for any oversights or imprecisions. AAA Biotech reserves the right to adjust any aspect of this datasheet at any time and without notice. It is the responsibility of the customer to inform AAA Biotech of any product performance issues observed or experienced within 30 days of receipt of said product. To see additional details on this or any of our other policies, please see our Terms & Conditions page.Item has been added to Shopping Cart
If you are ready to order, navigate to Shopping Cart and get ready to checkout.
